AMGN Declares A Head-to-Head Phase III; CNAT Reports Acceptance Of Abstract For AASLD Meeting

Amgen (AMGN) has claimed gaining regulatory approval for its biosimilar of Humira, AbbVie's (ABBV) mega blockbuster anti-inflammatory drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.